Business
Aclarion Receives Notice of Allowance for US Patent to Support Further Optimization of Accuracy and Reliability in the Nociscan Solution
Notice of Allowance is for the 23rd US Patent to be Awarded to Aclarion New Patent Allows Aclarion Exclusive Access to Enhanced Post-processing Techniques of
About this update from Aclarion, Inc.
[{"type":"text","content":"Notice of Allowance is for the 23rd US Patent to be Awarded to Aclarion\nNew Patent Allows Aclarion Exclusive Access to Enhanced Post-processing Techniques of Magnetic Resonance Spectroscopy (MRS) to Improve Data Quality\nAclarion's Patent Portfolio Continues to Grow in Support of a Platform Technology That can be Leveraged for Potential Future MRS Product Expansions Into Breast, Prostate, and Brain\nBROOMFIELD, CO - (NewMediaWire) - June 20, 2024 - Aclarion, Inc., (\"Aclarion\" or the \"Company\") (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for the 23rd US patent that will be issued to the Company. The patent relates to novel post-processing techniques to improve the quality of the spectral data derived from non-invasive MRS exams. This improved quality enables more accurate quantification of the chemical biomarkers used by the Nocican solution. Allowance of this patent protects Aclarion's market leader position as the world's only SaaS platform delivering advanced chemical biomarker data to help physicians non-invasively identify the source of chronic low back pain (cLBP).\n\"This patent marks yet another validation of Aclarion's unique commitment to engage expert engineering talent to overcome many of the issues that have historically challenged MRS,\" said Brent Ness, President and Chief Executive Officer at Aclarion. \"While these advancements are improvements to MRS science in general, we are especially excited by the continued expansion of our patent portfolio for our disruptive Nociscan platform to ultimately help doctors better locate, and potentially better treat, painful degenerated discs that are causing cLBP.\"\nMRS is an existing capability of leading magnetic resonance imaging (MRI) scanners which are commonly used today for medical imaging. MRI creates images of the soft tissue structures of the body while MRS generates spectral data information on the levels of various chemical biomarkers within the soft tissues such as proteins, carbohydrates, acids, etc. However, conventional MRS post-processing approaches can be challenging and fall short of g...